15M

(5Z)-7-{(1R,2R,3R,5S)-3,5-DIHYDROXY-2-[(1E,3S)-3-HYDROXY-5-PHENYLPENT-1-ENYL]CYCLOPENTYL}-N-ETHYLHEPT-5-ENAMIDE



Chemical Component Summary

Name(5Z)-7-{(1R,2R,3R,5S)-3,5-DIHYDROXY-2-[(1E,3S)-3-HYDROXY-5-PHENYLPENT-1-ENYL]CYCLOPENTYL}-N-ETHYLHEPT-5-ENAMIDE
SynonymsBIMATOPROST
Identifiers(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenyl-pent-1-enyl]cyclopentyl]-N-ethyl-hept-5-enamide
FormulaC25 H37 N O4
Molecular Weight415.57
TypeNON-POLYMER
Isomeric SMILESCCNC(=O)CCC\C=C/C[C@H]1[C@H](C[C@H]([C@@H]1\C=C\[C@H](CCc2ccccc2)O)O)O
InChIInChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
InChIKeyAQOKCDNYWBIDND-FTOWTWDKSA-N

Chemical Details

Formal Charge0
Atom Count67
Chiral Atom Count5
Bond Count68
Aromatic Bond Count6

Drug Info: DrugBank

DrugBank IDDB00905 
NameBimatoprost
Groups
  • approved
  • investigational
DescriptionBimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma.[L6877,L6892,L6898,L12069] Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth.[L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.[L4894]
Synonyms
  • Bimatoprost
  • Bimatoprostum
  • (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
Brand Names
  • Lumigan
  • Vistitan
  • Durysta
  • Lumigan Rc
  • Apo-bimatoprost
IndicationBimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.[L6877] Bimatoprost is also indicated to treat eyelash hypotrichosis.[L6910]
Categories
  • Amides
  • Antiglaucoma Preparations and Miotics
  • Antihypertensive Agents
  • Autacoids
  • Biological Factors
ATC-CodeS01EE03
CAS number155206-00-1

Drug Targets

NameTarget SequencePharmacological ActionActions
Prostaglandin F2-alpha receptorMSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAI...unknownagonist
Prostaglandin E2 receptor EP1 subtypeMSPCGPLNLSLAGEATTCAAPWVPNTSAVPPSGASPALPIFSMTLGAVSN...unknownagonist
Prostaglandin E2 receptor EP3 subtypeMKETRGYGGDAPFCTRLNHSYTGMWAPERSAEARGNLTRPPGSGEDCGSV...unknownagonist
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem5311027
ChEBICHEBI:51230
ChEMBLCHEMBL1200963
PharosCHEMBL1200963